Physician
Pain Medicine & Rehabilitation Group PC
Pain Medicine & Rehabilitation Group PC was paid $4.17M by Medicaid between Jan 2018 and Dec 2024, across 45 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 47% of everything it billed.
33Billing provider infoPAIN MEDICINE & REHABILITATION GROUP PC
BRENTWOOD, TN 37027
BRENTWOOD, TN 37027
33aNPI1770516080assigned 07/09/2006
33bProvider typePain Medicine (Physical Medicine & Rehabilitation) Physician
28Total paid$4.17M
24GClaims163,318
24DCodes billed45
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Physical Medicine & Rehabilitation) Physician providers in Tennessee
Rank by total paid#1 of 9
Median peer was paid$213K
This provider vs. median20×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,143 | $1.05M | |
| 2019 | 29,347 | $696K | |
| 2020 | 23,840 | $534K | |
| 2021 | 22,168 | $505K | |
| 2022 | 23,900 | $576K | |
| 2023 | 20,014 | $472K | |
| 2024incomplete | 15,906 | $339K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 47% | 67,457 | 58,074 | $1.97M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 19% | 41,460 | 36,548 | $781K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 15% | 14,113 | 11,966 | $608K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.3% | 20,408 | 17,241 | $264K |
| 64635 | 2.0% | 1,094 | 598 | $81K | |
| 27096 | 1.9% | 983 | 849 | $79K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.9% | 1,248 | 1,092 | $78K |
| 64636 | 1.2% | 1,125 | 592 | $52K | |
| 64493 | 1.1% | 1,189 | 598 | $44K | |
| 64483 | <1% | 775 | 572 | $40K | |
| 62323 | <1% | 357 | 266 | $35K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,841 | 1,642 | $35K |
33 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,676 | $27K |
| 64494 | <1% | 1,111 | $19K | |
| 64495 | <1% | 675 | $14K | |
| 95886 | <1% | 180 | $11K | |
| 62321 | <1% | 86 | $6K | |
| 95909 | <1% | 81 | $4K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,063 | $4K |
| 99441 | <1% | 584 | $3K | |
| 20610 | <1% | 155 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 64 | $3K |
| 62370 | <1% | 136 | $3K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 48 | $2K |
| 99205 | Prolong outpt/office vis | <1% | 28 | $2K |
| 20552 | <1% | 81 | $2K | |
| L0642 | Lumbar orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from l-1 to below l-5 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | <1% | 41 | $2K |
| 81025 | <1% | 375 | $1K | |
| 99406 | <1% | 194 | $813.97 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,200 | $784.54 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 63 | $583.98 |
| 20611 | <1% | 21 | $520.83 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 895 | $512.44 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 120 | $421.02 |
| 20553 | <1% | 15 | $402.39 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 54 | $233.05 |
| J2704 | Injection, propofol, 10 mg | <1% | 721 | $207.25 |
| 80305 | <1% | 67 | $202.50 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 30 | $76.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 41 | $39.58 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 27 | $4.85 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 169 | $4.81 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 125 | $0.10 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 1,076 | $0.00 |
| 77003 | 0% | 66 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNWOFIA, JOHN (MEDICAL DIRECTOR)